Pieris Inks €207M Discovery Deal with Daiichi Sankyo

The companies signed a collaboration and license agreement under which Pieris will use its Anticalin scaffold technology against two targets to be provided by Daiichi Sankyo.

Germany's Pieris AG has signed a drug discovery pact with Japan's Daiichi Sankyo. The contract will offer more than €7 million in an upfront payment and up to €200 million in fees, research funding and milestones. In the deal Pieris will use of its drug development platform to find two new drugs that can hit Daiichi Sankyo's targets.

"Our deal with Daiichi Sankyo demonstrates yet again the high value of the Anticalin technology and we're extremely proud to count Daiichi Sankyo among the growing list of industry leaders who are our

Related News

News Women in Pharma: Hiring Across the Gender Divide

In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond.

19 Oct 2023
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity

Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe...

18 Oct 2023
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests

A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test.

17 Oct 2023
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m

To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development.

16 Oct 2023
News Updated – Changing abortion pill access according to the US FDA and Supreme Court

After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug.

11 Sep 2023
News Revolutionising cancer treatment with mRNA-based therapeutics

Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours.

5 Sep 2023
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability

The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ...

28 Aug 2023
News Choosing the Right CDMO Partner: A Comprehensive Guide

Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...

28 Aug 2023

CPHI Online is the largest global marketplace in the pharma ingredients industry

Pieris Inks €207M Discovery Deal with Daiichi Sankyo

Related News

Position your company at the heart of the global Pharma industry with a CPHI Online membership

Request for general information